Duke Energy, CommScope and two biotech firms in the Triangle report their financials as earnings season continues. Here’s the latest:
Duke Energy
CHARLOTTE – Duke Energy Corp. (DUK) on Thursday reported second-quarter net income of $765 million, after reporting a loss in the same period a year earlier.
The Charlotte, North Carolina-based company said it had profit of 96 cents per share. Earnings, adjusted for non-recurring costs, came to $1.15 per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.12 per share.
The electric utility posted revenue of $5.76 billion in the period.
Duke Energy expects full-year earnings in the range of $5 to $5.30 per share.
Duke Energy shares have increased 17% since the beginning of the year, while the S&P’s 500 index has climbed 17%. The stock has increased 26% in the last 12 months.
CommScope
HICKORY – CommScope Holding Co. (COMM) on Thursday reported a loss of $153.8 million in its second quarter.
The Hickory, North Carolina-based company said it had a loss of 82 cents per share. Earnings, adjusted for one-time gains and costs, came to 43 cents per share.
The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 44 cents per share.
The wireless and broadband network technology company posted revenue of $2.19 billion in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $2.15 billion.
CommScope shares have risen 54% since the beginning of the year. The stock has more than doubled in the last 12 months.
BioCryst
DURHAM – BioCryst Pharmaceuticals Inc. (BCRX) on Thursday reported a loss of $43.2 million in its second quarter.
The Durham, North Carolina-based company said it had a loss of 24 cents per share.
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 22 cents per share.
The drugmaker posted revenue of $50 million in the period, surpassing Street forecasts. Four analysts surveyed by Zacks expected $31.4 million.
BioCryst shares have more than doubled since the beginning of the year. The stock has nearly quadrupled in the last 12 months.
Chimerix
DURHAM – Chimerix Inc. (CMRX) on Thursday reported a loss of $17.8 million in its second quarter.
The Durham, North Carolina-based company said it had a loss of 21 cents per share.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share.
The biopharmaceutical company posted revenue of $391,000 in the period.
Chimerix shares have climbed 34% since the beginning of the year. The stock has risen 94% in the last 12 months.
